PATENT CLAIM ANALYSIS

Application Number: 16292011
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-06
Patent Classification: ["514", "364000"]

Abstract:
The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Claim (Index 74):
The method of  claim 66 , wherein the HDAC inhibitor is SAHA, TSA, TPX, MS-275, Valproic Acid, or CHAP31, or a functional equivalent, analog, derivative or salt thereof, or a combination thereof.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 99.0
- Lexical Diversity: 1.93878
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15317559', '16012536', '14783344', '14506889', '12022977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7740363465010832
- 35 USC 102 Novelty (BERT): 0.582842586413038
- Combined Prediction Score: 0.7549169704922787
- Mean Citation Score: 372.964488
- Max Citation Score: 610.5238
- Similarity Product: 347.06220914790634

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test